Summit Therapeutics (SMMT) Current Deferred Revenue (2018 - 2022)
Summit Therapeutics' (SMMT) quarterly Current Deferred Revenue came in at $3.2 million in Q2 2022, down 56.95% YoY from $7.5 million in Q2 2021, and down 36.61% on a QoQ basis from $5.1 million in Q1 2022.
Summit Therapeutics (SMMT) Current Deferred Revenue (2018 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 5 years of Current Deferred Revenue data on file, last reported at $3.2 million in Q2 2022.
- Quarterly Current Deferred Revenue fell 56.95% year-over-year to $3.2 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $3.2 million (down 56.95% YoY) and the FY2021 annual result came in at $7.9 million, down 11.19% from the prior year.
- Current Deferred Revenue eased to $3.2 million in Q2 2022, from $5.1 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $18.6 million in Q1 2018 to a low of $464133.6 in Q4 2019.
- A 5-year average of $6.8 million and a median of $7.1 million in 2020 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2019 — Current Deferred Revenue tumbled 94.21% — and 2020, when it soared 512.02%.
- Tracing SMMT's Current Deferred Revenue over 5 years: stood at $8.0 million in 2018, then slumped by 81.79% to $1.5 million in 2019, then soared by 512.02% to $8.9 million in 2020, then fell by 11.19% to $7.9 million in 2021, then plunged by 59.3% to $3.2 million in 2022.
- The last three Current Deferred Revenue figures came in at $3.2 million (Q2 2022), $5.1 million (Q1 2022), and $7.9 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 3.23 Mn |
| Mar 31, 2022 | 5.10 Mn |
| Dec 31, 2021 | 7.94 Mn |
| Sep 30, 2021 | 7.51 Mn |
| Jun 30, 2021 | 7.51 Mn |
| Mar 31, 2021 | 7.81 Mn |
| Dec 31, 2020 | 8.94 Mn |
| Sep 30, 2020 | 7.11 Mn |
| Mar 31, 2020 | 2.22 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Oct 31, 2019 | 464,133.65 |
| Jul 31, 2019 | 3.99 Mn |
| Jan 31, 2019 | 4.33 Mn |
| Oct 31, 2018 | 8.02 Mn |
| Jul 31, 2018 | 3.34 Mn |
| Apr 30, 2018 | 18.47 Mn |
| Jan 31, 2018 | 18.64 Mn |